The Demise of the Absorb BVS: Lessons Learned From the Discontinuation of a Disappearing Stent

Abstract

Keywords

absorbable implants angioplasty critical limb ischemia drug-eluting technology infrapopliteal artery ischemia lower extremity peripheral artery disease occlusion polymers stenosis tibial artery

Get full access to this article

View all access options for this article.

References

Varcoe

Thomas

Lennox

AF.

Three-year results of the Absorb everolimus-eluting bioresorbable vascular scaffold in infrapopliteal arteries. J Endovasc Ther. 2018;25:694–701.

Ali

Serruys

Kimura

et al . 2-year outcomes with the Absorb bioresorbable scaffold for treatment of coronary artery disease: a systematic review and meta-analysis of seven randomised trials with an individual patient data substudy. Lancet. 2017;390:760–772.

Onuma

Sotomi

Shiomi

et al . Two-year clinical, angiographic, and serial optical coherence tomographic follow-up after implantation of an everolimus-eluting bioresorbable scaffold and an everolimus-eluting metallic stent: insights from the randomised ABSORB Japan trial. EuroIntervention. 2016;12:1090–1101.

Varcoe

Thomas

Rapoza

et al . Lessons learned regarding handling and deployment of the Absorb bioresorbable vascular scaffold in infrapopliteal arteries. J Endovasc Ther. 2017:24;337–341.

Stone

Abizaid

Onuma

et al . Effect of technique on outcomes following bioresorbable vascular scaffold implantation: analysis from the ABSORB trials. J Am Coll Cardiol. 2017;70:2863–2874.

Kimura

Kozuma

Tanabe

et al . A randomized trial evaluating everolimus-eluting Absorb bioresorbable scaffolds vs.everolimus-eluting metallic stents in patients with coronary artery disease: ABSORB Japan. Eur Heart J. 2015;36:3332–3342.

Stone

Gao

Kimura

et al . 1-year outcomes with the Absorb bioresorbable scaffold in patients with coronary artery disease: a patient-level, pooled meta-analysis. Lancet. 2016;387:1277–1289.

Kereiakes

Ellis

Popma

et al . Evaluation of a fully bioresorbable vascular scaffold in patients with coronary artery disease: design of and rationale for the ABSORB III randomized trial. Am Heart J. 2015;170:641–651.e3.

Wykrzykowska

Kraak

Hofma

et al . Bioresorbable scaffolds versus metallic stents in routine PCI. N Engl J Med. 2017;376:2319–2328.

10.

Bangalore

Bezerra

Rizik

et al . The state of the Absorb bioresorbable scaffold: consensus from an expert panel. JACC Cardiovasc Interv. 2017;10:2349–2359.

11.

Gori

Weissner

Gönner

et al . Characteristics, predictors, and mechanisms of thrombosis in coronary bioresorbable scaffolds: differences between early and late events. JACC Cardiovasc Interv. 2017;10:2363–2371.

12.

Sotomi

Suwannasom

Serruys

et al . Possible mechanical causes of scaffold thrombosis: insights from case reports with intracoronary imaging. EuroIntervention. 2017;12:1747–1756.

13.

Pache

Kastrati

Mehilli

et al . Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STEREO-2) trial. J Am Coll Cardiol. 2003;41:1283–1288.

14.

Kolandaivelu

Swaminathan

Gibson

et al . Stent thrombogenicity early in high risk interventional settings is driven by stent design and deployment, and protected by polymer-drug coatings. Circulation. 2011;123:1400–1409.

15.

Sotomi

Onuma

Collet

et al . Bioresorbable scaffold: the emerging reality and future directions. Circ Res. 2017;120:1341–1352.

16.

Mustapha

Diaz-Sandoval

Saab

Infrapopliteal calcification patterns in critical limb ischemia: diagnostic, pathologic and therapeutic implications in the search for the endovascular holy grail. J Cardiovasc Surg (Torino). 2017;58:383–401.

17.

Drueke

TB.

Arterial intima and media calcification: distinct entities with different pathogenesis or all the same?

Clin J Am Soc Nephrol. 2008;3:1583–1584.

18.

Räber

Magro

Stefanini

et al . Very late coronary stent thrombosis of a newer generation everolimus-eluting stent compared with early generation drug-eluting stents: a prospective cohort study. Circulation. 2012;125:1110–1125.

19.

Tada

Byrne

Simunovic

et al . Risk of stent thrombosis among bare-metal stents, first-generation drug-eluting stents, and second-generation drug-eluting stents: results from a registry of 18,334 patients. JACC Cardiovasc Interv. 2013;6:1267–1274.

20.

Stone

Witzenbichler

Weisz

et al . Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study. Lancet. 2013;382:614–623.

21.

Katsanos

Kitrou

Spiliopoulos

et al . Comparative effectiveness of plain balloon angioplasty, bare metal stents, drug-coated balloons, and drug-eluting stents for the treatment of infrapopliteal artery disease: systematic review and Bayesian network meta-analysis of randomized controlled trials. J Endovasc Ther. 2016;23:851–863.

22.

Jaff

Cahill

Andrew

et al . Clinical outcomes and medical care costs among Medicare beneficiaries receiving therapy for peripheral arterial disease. Ann Vasc Surg. 2010;24:577–587.

23.

Ryan

Linde-Zwirble

Engelhart

et al . Temporal changes in coronary revascularization procedures, outcomes, and costs in the bare-metal stent and drug-eluting stent eras: results from the US Medicare program. Circulation. 2009;119:952–961.

24.

Armstrong

Cohen

Courric

et al . Diabetic foot ulcers and vascular insufficiency: our population has changed, but our methods have not. J Diabetes Sci Technol. 2011;5:1591–1595.